Appendix 4E and FY26 Annual Report
Released
Released
Announcement PDF
RECCE PHARMACEUTICALS LTD
ABN 73 124 849 065
Current Reporting Period: 30 June 2026
Previous Reporting Period: 30 June 2025
Revenue from ordinary activities - - 0%
Loss from ordinary activities after tax
attributable to members (14,961,430) (21,428,089) -30%
Net loss for the period attributable to members (14,961,430) (21,428,089) -30%
Brief Explanation of Results
Operational Report
•
•
•
•
Appendix 4E
Final Report for the financial year ended 30 June 2026
Results for Announcement to the Market
12 months to
30 June 2025
$
% Change
12 months to
30 June 2026
$
During the reporting period, significant advances were made in support of the development of the Company's
anti-infective portfolio. Some of the highlights for the full year to 30 June 2026 were as follows:
Research Abstract and Poster presentation at the 2025 Military Health System Research Symposium
(MHSRS). The abstract presents expanded data of RECCE® 327 demonstrating activity against multiple high-
priority bioterrorism pathogens in laboratory testing.
Statistically significant positive efficacy data against two clinically significant antibiotic-resistant
pathogens, including wound healing/wound contraction data for burn wounds in rat infection models. The
study assessed the efficacy of R327G against Methicillin-resistant Staphylococcus aureus (MRSA) and
Pseudomonas aeruginosa (P. aeruginosa), two clinically significant antibiotic-resistant pathogens. R327G
achieved a statistically significant reduction in bacterial load compared to untreated control groups, with
bacterial counts reduced substantially by Day 4 and highly significant reductions observed by Day 8.
Patient dosing underway for Registrational Phase 3 clinical trial for Diabetic Foot Infections (DFI), with five
(5) clinical study sites now activated across Indonesia, one of the world's largest DFI patient populations.
Based on the approved statistical plan the Company expects to meet a highly statistically significant
positive endpoint after dosing approximately 155 patients. The approved protocol has a built-in interim
analysis as well as Expedited Regulatory Review status.
Passing of Recce Pharmaceuticals founder and the inventor of Recce's technology platform, Dr Graham JH
Melrose BSc (Hons), PhD, MBA, FRACI, CChem and FAICD. Dr Melrose founded Recce in 2007, drawing
upon both his business and scientific expertise as the original inventor of the Company's technology
•
•
•
•
•
•
•
•
•
•
•
•
Appendix 4E
Final Report for the financial year ended 30 June 2026
Positive preclinical data from an ongoing research program conducted by Murdoch Children's Research
Institute (MCRI). The study investigated the therapeutic efficacy of RECCE® 327 (R327) in a validated model
of Hospital/Ventilator Acquired Pneumonia (HAP/VAP) caused by carbapenem-resistant Acinetobacter
baumannii (CRAB) – a critical global health priority pathogen. Nebulised R327 treatment resulted in a 4-log
reduction, corresponding to >99.99% lower bacterial burden in the lungs.
Hong Kong Special Administrative Region formally granted Patent Family 4 for Recce's Anti-Infectives,
expiry 2041.
Advanced Overseas Finding received for up to A$85 million for Synthetic Antibiotic Research &
Development (R&D) applicable expenditure by Department of Industry, Science and Resources.
Annual Report for the financial year ended 30 June 2025 was released.
Cash refund of AUD $5.3m Research and Development (R&D) Tax Incentive rebate from the Australian
Taxation Office for the financial year ending 30 June 2025.
Entry into a Cooperative Research and Development Agreement (CRADA) with the United States Army
Institute of Surgical Research (USAISR), the U.S. Army's leader in Combat Casualty Research and Burn Care,
to evaluate R327G in reducing bioburden in burn wounds using the USAISR Walker-Mason rat model.
Online Investor Webinar held on 19 March 2026, featuring presentations from experts across key program
areas, including the Company's Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia
and U.S. Department of War burn wound program.
Brazilian National Institute of Industrial Property (INPI) formally granted a Family 4 patent for RECCE® Anti-
Infectives in Brazil, expiring 2041, alongside Australia, Canada, China, Hong Kong, Israel and Japan.
Successful completion of comprehensive routine regulatory inspection by the Indonesian National Agency
of Drug and Food Control (Badan POM) of the Phase 3 clinical trial site in Indonesia, with no findings noted
that prevent the study from continuing. The inspection represented a critical de-risking milestone for
Recce's registrational Phase 3 clinical trial.
Entry into a non-binding term sheet with a leading Middle Eastern pharmaceutical company for an
exclusive 10-year licensing arrangement covering the commercial sales and distribution of R327G for the
treatment of Diabetic Foot Infections across the Middle East and North Africa (MENA) region.
Human Research Ethics Committee (HREC) approval received to advance the Australian Phase 3 clinical
trial to a Pivotal Phase 3 trial, with protocol amendment expanding patient eligibility to include Mild and
Moderate DFI, and expanding the trial to include infected ulcers below the knee in addition to infected
foot ulcers.
Announcement of capital raise of AUD $4.0 million via institutional placement at A$0.40 per share, with
launch of Share Purchase Plan (SPP) to provide eligible shareholders the opportunity to subscribe for up to
AUD $4.0 million of shares on the same terms.
Financial Report
Dividends
Amount per
Security
Percentage
Franked
N/A
Nil
Final Dividend
N/A
Nil
Interim Dividend
N/A
N/A
Date the Dividend is Payable:
N/
N/A
Record Date for determining entitlements to the Dividends: A
Net Tangible Assets per Security
As at 30 June 2026 (cents) (5.78)
(1.06)
As at 30 June 2025 (cents)
The loss per share has decreased during the year to 5.17 cents (2025: 9.04 cents).
The Group’s focus is on progressing RECCE® 327 into human clinical trials.
The Company did not declare a dividend during the financial year and has not declared a dividend since the
end of the financial year.
The operating loss has decreased to $14,961,430 (2025: loss of $21,428,089) as a result of decreased
expenditure on research and development. The annual loss was after a R&D tax incentive of $8,878,182 (2025:
$6,738,274).
Appendix 4E
Final Report for the financial year ended 30 June 2026
This announcement has been approved for release by Recce Pharmaceuticals Board.
Annual
Report
2026
ASX: RCE, FSE: R9Q
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)
is developing a New Class of Synthetic Anti-
Infectives designed to address the urgent global
health problems of antibiotic-resistant superbugs.
Recce’s anti-infective pipeline includes three
patented, broad-spectrum, synthetic polymer anti-
infectives: RECCE®
327 (R327) as an intravenous
and topical therapy that is being developed for the
treatment of serious and potentially life-threatening
infections due to Gram-positive and Gram-negative
bacteria, including their superbug forms; RECCE®
435 (R435) as an orally administered therapy
for bacterial infections; and RECCE®
529 (R529)
for viral infections. Through their multi-layered
mechanisms of action, Recce’s anti-infectives have
the potential to overcome the processes utilised
by bacteria and viruses to overcome resistance –
a current challenge facing existing antibiotics.
The World Health Organization (WHO)
added R327, R435, and R529 to its list of
antibacterial products in clinical development
for priority pathogens, recognising Recce’s
efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious
Disease Product designation under the
Generating Antibiotic Incentives Now (GAIN)
Act, providing Fast Track Designation and
5 years of market exclusivity post approval.
R327 is also included on The Pew Charitable
Trusts’ Global New Antibiotics in Development
Pipeline as the sole synthetic polymer and
sepsis drug candidate in development.
Recce wholly owns its automated
manufacturing, supporting current clinical
trials. Recce’s anti-infective pipeline aims to
address synergistic, unmet medical needs by
leveraging its unique technologies.
About Us
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
1
Contents Business Highlights 2
Letter from Chairman 4
Letter from CEO 6
Overview of Company Activities 8
Conference Engagement 14
In Memoriam 15
Board of Directors and Key
Management Personnel
16
Financial Report 19
Corporate Directory 88 RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
2
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
Listed below are the main corporate developments for the 2026 Financial Year.
Business
Highlights
Clinical and Preclinical
Diabetic Foot Infections - Registrational Phase 3 Clinical Trial in Indonesia
• Patient dosing commenced in the Registrational Phase 3 Clinical Trial for the treatment of
Diabetic Foot Infections (DFI) in Indonesia, with five clinical study sites activated across one of
the world’s largest DFI patient populations.
• The trial is one of the largest DFI studies in the world, with up to 310 patients randomised to
receive either RECCE®
327 Topical Gel (R327G) or placebo, and an approvable interim data
analysis at 155 patients.
• The Indonesian National Agency of Drug and Food Control (Badan POM) successfully
completed a comprehensive routine regulatory inspection of a Phase 3 trial site with no findings
that prevent the study from continuing.
Diabetic Foot Infections - Registrational Phase 3 Trial in Australia
• Human Research Ethics Committee (HREC) approval secured to accelerate Recce’s global
Phase 3 DFI strategy, including elevation of the Australian Acute Bacterial Skin and Skin-
Structure Infections (ABSSSI) registrational trial, patient dosing commenced and expansion of
the study protocol to include Moderate DFI patients.
U.S. Department of War Burn Wound Program
• Recce entered into a second Cooperative Research and Development Agreement (CRADA)
with the U.S. Army Institute of Surgical Research, the U.S. Army’s leader in Combat Casualty
Research and Burn Care, to evaluate R327G for burn wound infections.
• Recce’s first CRADA with the U.S. Army Medical Research Institute of Infectious Diseases and
the Company’s US$2 million Congressionally Directed Medical Research Program grant award.
• Statistically significant positive preclinical efficacy data for R327G against Methicillin-resistant
Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in burn wound rat infection
models. R327G’s antimicrobial performance exceeded that of Soframycin, with statistically
significant wound contraction demonstrated.
Preclinical - Inhaled R327 in Hospital/Ventilator-Acquired Pneumonia
• Positive preclinical data were reported from the ongoing research program conducted by
Murdoch Children’s Research Institute. The study investigated the therapeutic efficacy of
RECCE®
327 (R327) in validated mice models of Hospital/Ventilator-Acquired Pneumonia
(HAP/VAP) caused by carbapenem-resistant Acinetobacter baumannii.
• Nebulised R327 treatment resulted in a 4-log reduction, corresponding to >99.99% lower
bacterial burden in the lungs, with bacterial counts approaching the lower limit of detection
demonstrating potent local infection control.
3
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
Commercial and Operational
• Signed a non-binding Middle East licensing term sheet, covering 12 countries across the MENA
region, for RECCE®
327.
• AUD$5.3 million R&D Tax Incentive Rebate received from the Australian Taxation Office for
FY2025.
• Advanced Overseas Finding awarded for up to AUD$85 million for Synthetic Antibiotic Research
& Development applicable expenditure by the Department of Industry, Science and Resources,
Recce’s R&D activities undertaken outside Australia are eligible for the 43.5% R&D Tax Incentive
across a three-year period.
• Successful completion of a Placement and Share Purchase Plan (SPP) raising AUD$6.4 million
(before costs), strengthening the Company’s balance sheet to support continued clinical
development.
• Key Opinion Leader Investor Webinar hosted, featuring updates on the Phase 3 Clinical Trial for
Diabetic Foot Infections in Indonesia and the U.S. Department of War burn wound program.
Regulatory and Intellectual Property
• Family 4 patent granted for RECCE®
Anti-Infectives in Hong Kong, expiring 2041 — the
Company’s sixth Family 4 patent.
• Family 4 patent granted for RECCE®
Anti-Infectives in Brazil, expiring 2041, alongside Australia,
Canada, China, Hong Kong, Israel, Japan and Vietnam*.
• Abstract and Poster Presentation accepted and delivered at the 2025 US Military Health System
Research Symposium presenting data of RECCE®
327 demonstrating activity against multiple
high-priority bioterrorism pathogens.
*announced post financial year.
4
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
Dear Shareholders,
We are pleased to present Recce Pharmaceuticals’
annual report for the financial year ended 30
June 2026. This has been a year defined by late-
stage clinical momentum, further validation of our
platform technology, and continued strengthening
of our position at the forefront of the global fight
against antimicrobial resistance.
Recce remains focused on delivering
near-term clinical and commercial
outcomes that we believe will create
significant value for our shareholders
and for the patients we are working to
serve.
Financial Year 2026 began with one of Recce’s most significant milestones. We have expanded our
global regulatory strategy with the addition of a pivotal Registrational Phase 3 Clinical Trial for Diabetic
Foot Infections to be conducted in Australia. Moreover, our current ongoing Phase III trial in Indonesia
now has five clinical sites activated, and with patient dosing well underway, the program is progressing
toward the approvable interim data readout.
Of particular note is the recent successful completion of a comprehensive routine regulatory inspection
by Indonesia’s National Agency of Drug and Food Control (Badan POM), which further underscores the
quality and integrity of our clinical operations. Regulatory approval in Indonesia would represent the
Company’s first commercial milestone and open the door to further approvals across the ASEAN region.
Letter from
the Chairman
Expanding Our Global Footprint Through Strategic Licensing
During FY2026, in conjunction with Recce’s
clinical operations, the Company took
an important step in our international
commercialisation strategy with the signing of
a non-binding term sheet with a leading Middle
Eastern pharmaceutical company, an established
pharmaceutical group with manufacturing and
distribution presence across the Middle East. The
proposed partnership covers 12 countries across
the MENA region, anchored by Saudi Arabia and
its surrounding markets.
This agreement reflects a deliberate extension of
our approach: having built a regulatory and clinical
foundation in Indonesia and Australia, we are now
positioning RECCE®
327 for entry into a region
defined by significant unmet need in infectious
disease management, substantial healthcare
investment, and regulatory pathways receptive
to novel anti-infective therapies. Specifically, the
Middle East and North Africa (MENA) region has
the highest age-standardised diabetes prevalence
of any region.
5
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
The MENA opportunity is consistent with our
broader strategy of pursuing capital-efficient,
partnership-led market expansion — leveraging
our clinical data package and international
designations to secure agreements with
established regional operators, while Recce’s
internal resources remain focused on advancing
our late-stage clinical programs in Indonesia,
Australia and the United States. We look forward
to progressing this relationship and see it as an
important step for Recce to extend the reach of
R327G into additional territories over time.
U.S. Government
Collaborations
International recognition of Recce’s technology
continued to grow during the year, most notably
through our expanding collaboration with
the U.S. Government, which now represents
a significant and growing second pillar of the
Company’s value.
We entered into a second Cooperative Research
and Development Agreement (CRADA) with
the U.S. Army Institute of Surgical Research
(USAISR), adding to our existing partnership
with the U.S. Army Medical Research Institute of
Infectious Diseases (USAMRIID). Together with
the USD $2 million Congressionally Directed
Medical Research Program (CDMRP) grant, these
agreements reflect accelerating interest from U.S.
military and government institutions in R327G’s
potential as a next-generation anti-infective for
both combat and civilian applications — and
demonstrate that R327G is being taken seriously
at the highest levels of U.S. military medical
research as a potential solution for burn wound
infections, one of the most challenging and drug-
resistant infection types encountered in military
and trauma settings. Critically, these agreements
with the U.S. Department of War underscore its
desire to secure an anti-infective with broad-
spectrum activity that will not succumb to
antimicrobial resistance.
Preclinical data published during the year
reinforced this confidence: R327G demonstrated
statistically significant reductions in bacterial load
against MRSA and Pseudomonas aeruginosa in
burn wound rat infection models, outperforming
Soframycin on both antimicrobial efficacy and
wound healing outcomes. R327G was applied
once daily compared to twice-daily Soframycin
— a meaningful advantage for patients, clinicians,
and health economics.
The year also saw our team present research
on R327G at the 2025 Military Health System
Research Symposium, the premier U.S. military
medical research meeting, further elevating
Recce’s global profile.
A Growing Preclinical
Pipeline
Positive data from our Anti-Infective Research
Unit at the Murdoch Children’s Research Institute
(MCRI) continue to expand the evidence base
for R327 beyond its current clinical programs.
During the year, nebulised R327 demonstrated
a 4-log reduction (>99.99%) in bacterial burden
in a validated lung infection model, approaching
the lower limit of detection. This positions R327
to become a clinically relevant inhaled therapy
with a meaningful practical advantage over
other established therapies such as meropenem,
the current standard of care, which cannot be
effectively nebulised.
Looking Ahead
Despite challenging markets, Recce remains
focused on delivering near-term clinical and
commercial milestones that we believe will create
significant value for our shareholders and for the
patients we are working to serve. Our primary
goals remain focused on delivering bold, science-
and technology-driven solutions to address one
of, if not, the most significant global challenges in
healthcare.
On behalf of the Board, I thank our shareholders,
clinical collaborators, and partners for their
continued trust and support.
Sincerely,
Dr John Prendergast
Executive Chairman
6
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
Conducted to both TGA and US FDA
regulatory standards, the Australian
trial forms a core part of Recce’s dual-
market approval strategy, supporting
future submissions in Australia and
the United States.
Dear Shareholders,
It is with great pleasure that I present the
development and commercial initiatives undertaken
by Recce Pharmaceuticals over the financial year
ended 30 June 2026. This year has seen the
Company transform into an active, late-stage
clinical organisation with patients enrolled, data
accruing, and our lead program progressing toward
its first regulatory approval milestone.
Letter from
the CEO
Two Phase 3 Clinical Programs Advancing Toward Approval
Recce is progressing two Registrational Phase 3
Clinical Trials for Diabetic Foot Infections (DFI),
reinforcing the global development pathway for
RECCE®
327 Topical Gel (R327G) across both the
Indonesian and Australian regulatory markets.
In Indonesia, patient dosing is ongoing across
five activated sites, with the trial on course to
deliver its approvable interim data readout at 155
patients treated. The program uses the Lipsky
Scale for clinical response assessment — an
FDA-recognised method — and is supported
by Indonesia’s Expedited Regulatory Review
pathway, designed to facilitate rapid approval
of genuinely needed therapies. A major de-
risking milestone was reached during the year
when Indonesia’s National Agency of Drug and
Food Control government agency, Badan POM,
completed a comprehensive routine regulatory
inspection of a Phase 3 trial site with no adverse
findings, reflecting the exceptional quality of
our clinical operations and giving the Board and
management strong confidence in the integrity
of the data being generated.
In Australia, the Company received Human
Research Ethics Committee (HREC) approval to
elevate its registrational Phase 3 DFI trial, including
an expansion of the study population to include
Moderate DFI patients — who, together with
Mild DFI, represent approximately 80% of all DFI
presentations. Conducted to both TGA and US FDA
regulatory standards, the Australian trial forms a
core part of Recce’s dual-market approval strategy,
supporting future submissions in Australia and the
United States.
Our Phase II clinical data remain compelling: R327G
demonstrated a 93% primary efficacy endpoint
over 14 days, with an 86% clinical response by
day 7, and no serious adverse events. Both Phase
3 trials are designed to replicate these outcomes
in larger, registrational settings, and we are
encouraged by the consistency of progress across
our global DFI program to date.
7
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
Funding and Financial
Position
FY2026 has been a year of sound financial
management. The receipt of A$5.3 million in
R&D tax rebates, including a further A$3.7 million
received on 2 July 2026, provides meaningful
non-dilutive funding to accelerate our clinical
development and commercial objectives.
The award of an AusIndustry Advanced Overseas
Finding of up to AUD$85 million further
underpins the long-term non-dilutive funding
runway available to the Company, extending
the 43.5% rebate to all qualifying R&D activities
conducted globally over the next three years.
Complementing this non-dilutive support, the
Company successfully finalised a Placement and
Share Purchase Plan (SPP) to raise AUD$6.4
million (before costs), building on the AUD$15.8
million equity raising completed in FY25 and
taking total equity capital raised across the
two years to AUD$22.2 million. The Company
also continues to hold its debt facility of up to
~AUD$30 million (US$20 million) with Avenue
Capital Group, established in FY25, in support of
our Phase 3 clinical trial activities, manufacturing,
regulatory submissions and market launch
preparation for R327G.
Continued support from institutional and
retail shareholders, alongside our non-dilutive
funding sources, strengthens our balance sheet
and positions Recce to execute on its near-
term clinical and commercial milestones while
maintaining a prudent financial footing.
Intellectual Property and
Global Recognition
Our patent portfolio reached new highs this year,
with Family 4 patents granted in Hong Kong and
Brazil, our sixth and seventh Family 4 patents
respectively, extending Recce’s commercial
protection into South America’s largest antibiotic
market and a key Asia-Pacific financial hub. The
portfolio now comprises over 40 patents and
patent applications across four families in the
world’s major markets, with protection extending
out to 2041.
R327 continues to be recognised at the highest
international levels. Its listing in the World Health
Organization 2025 Global Antibacterial Pipeline
Report as the sole synthetic polymer antibiotic in
clinical
development, alongside its FDA Qualified
Infectious Disease Product designation and Fast
Track status, positions Recce uniquely in the
global fight against antimicrobial resistance.
Tribute to Our Founder
This year we also lost our founder and inventor,
Dr Graham JH Melrose. His extraordinary
scientific curiosity gave rise to the RECCE®
platform we continue to advance every day,
and his mission to make antibiotic resistance
history guides us still. Under his leadership,
Recce grew from a bold concept into a publicly
listed company recognised internationally for its
unique anti-infective technologies, and his vision
continues to shape the direction of everything
we do. We are determined to honour his legacy
by seeing R327 reach the patients who need it.
Looking Ahead
With the Phase 3 trials advancing, two active U.S.
Government programs, a strengthening patent
portfolio, and meaningful non-dilutive funding
secured, Recce enters FY2027 with clear near-
term value catalysts in sight. We are focused on
delivering our interim data readout, pursuing
our regulatory approval pathway in Indonesia,
and progressing licensing negotiations that
could further accelerate our path to commercial
impact.
We are proud of what Recce has accomplished
this year — as a clinical-stage innovator, as a
financially disciplined organisation, and as a team
committed to improving outcomes for patients
suffering from some of the world’s most difficult
infections.
On behalf of the management team, I thank our
shareholders, partners, and all those working
alongside us for their continued support and
belief in our mission.
James Graham
Managing Director & Chief Executive Officer
8
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
Overview of
Company Activities
In FY2026, Recce Pharmaceuticals made strong progress across its clinical, preclinical,
commercial, operational and intellectual property programs as it advances its pipeline
of synthetic anti-infectives targeting serious, drug-resistant infections.
c
2
Ongoing Phase 3
Clinical Trials
12
Countries across
MENA region
15
Patent
Jurisdictions
85M
Advanced
Overseas Finding
AUD$
9
Human Clinical Trials
R327 Topical Programs
Registrational Phase 3 Clinical Trial
in Indonesia for Diabetic Foot Infections
The trial is a randomised, double-blind, placebo-
controlled study enrolling up to 310 DFI patients.
The trial’s primary objective is to assess the clinical
response of the DFI according to the Lipsky Scale,
the preferred and FDA-recognised method for
evaluating DFI treatment outcomes. Secondary
endpoints include total DFI wound score and the
safety of R327G including clinical observations and
adverse events.
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
TRIAL SNAPSHOT
Location: Indonesia
Program: Phase 3 Registrational
Target enrolment: Up to 310 patients
Interim readout: 155 patients
Trial Overview
Based on the approved statistical plan, the Company expects to meet a highly statistically significant
positive endpoint after dosing approximately 155 patients. The Indonesian Drug and Food Regulatory
Authority (Badan POM) approved protocol includes a built-in interim analysis as well as Expedited
Regulatory Review status.
During the year, Badan POM completed a
comprehensive routine regulatory inspection
of a Phase 3 trial site in Indonesia. The
inspection covered trial conduct, site
processes, data integrity, and compliance
with Good Clinical Practice (GCP) standards.
The outcome was the completion of the
inspection with no findings noted that would
prevent the study from continuing. This is
a key regulatory milestone that reinforces
the quality of Recce’s clinical operations in
Indonesia.
Regulatory Inspection Milestone
The Phase 3 program builds directly on the
strong results from Recce’s Phase II ABSSSI
clinical trial, which demonstrated a 93%
primary efficacy endpoint over 14 days and
an 86% clinical response by day 7, with no
serious adverse events. R327G was shown
to resolve infections in DFI patients, and the
Phase 3 protocol was designed with minimal
changes to replicate these outcomes in the
registrational setting.
Clinical Foundation
10
Registrational Phase 3 Clinical Trial
in Australia for Diabetic Foot Infections
Recce Pharmaceuticals is also advancing a
Registrational Phase 3 clinical trial of R327G for
the treatment of DFI in Australia, conducted to
both TGA and US FDA regulatory standards.
Indonesia ranks fifth in the world for diabetes
prevalence, with over 20.9 million adults
(approximately 11.3% of the adult population)
living with the disease. In-hospital treatment
costs for DFI patients average AUD ~$6,000
per patient, rising substantially for amputees.
With approximately 60% of all diabetic foot
ulcers developing infection, which can progress
to sepsis, gangrene, amputation, and death,
there is an urgent and large unmet medical
need.
Regulatory approval in Indonesia is expected
to support further approval pathways across
ASEAN member states, including Malaysia,
Thailand, Singapore, and the Philippines,
representing a broader market opportunity of
approximately US$1.5 billion.
The Indonesian Opportunity
RECCE
PHARMACEUTICALS
ANNUAL
REPORT
2026
20.9M adults living with diabetes
5th in world for diabetes prevalence
~60% develop an infected foot ulcer
~AUD$6,000 avg. treatment cost
~US$1.5B ASEAN opportunity
TRIAL SNAPSHOT
Location: Australia
Program: Phase 3 Registrational
Regulatory standards: TGA and US FDA
The Australian Phase 3 for DFI was previously
categorised as a randomised, double-
blind, placebo-controlled study. The study
protocol has now been amended to include a
randomised, active-controlled non-inferiority
study with patients treated with either R327G
or 1 of 4 established physician-selected
antibiotic treatment options used in the
management of DFI.
Trial Overview
During the year, the Company received Human
Research Ethics Committee (HREC) approval
for a protocol amendment expanding the trial
to include Moderate DFI patients, in addition
to Mild DFI. Mild and Moderate DFI together
represent approximately 80% of all DFI
presentations, broadening t
Share your feedback
Discover